ArticleKidney3602026
Development of Urinalysis Screening Criteria for Rhabdomyolysis in Acute Kidney Injury.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key pointsRhabdomyolysis accounts for approximately 7%-10% of AKI cases but is frequently missed because creatine kinase testing is rarely performed. Automated electronic screening of urinalysis parameters with clinical decision support to order creatine kinase may be a viable mechanism to increase rhabdomyolysis diagnosis.
backgroundRhabdomyolysis (RM) is the etiology in 7%-10% of cases of AKI and benefits from early, aggressive volume repletion. RM as an etiology of AKI is often missed in clinical setting as it requires specific diagnostic testing (creatine kinase [CK] testing). We evaluated various criteria that could be applied to urinalysis (UA) to identify individuals at elevated likelihood of RM.
methodsA retrospective electronic chart review of adult inpatients hospitalized at the Yale New Haven Hospital was performed between January 2020 and December 2022. A total of 12 screening criteria were formulated using combinations of heme (≥1+, ≥2+, and ≥3+) and red blood cells (RBCs; ≤5, ≤10, ≤20, and ≤30) per high power field thresholds from the closest UA before AKI. The accuracy was assessed using post-AKI CK >1000 U/L as the definition of RM diagnosis.
resultsA total of 12,273 patients were included of which 20.5% patients had serum CK levels checked after AKI. Of those, 222 (8.8%) met the diagnostic criteria for RM. The median time from laboratory AKI diagnosis to CK measurement was 2.7 (0.9-6.5) days. UA criterion 1.4 (≥1 heme and ≤30 RBCs) met by 35.1% demonstrated the highest sensitivity for RM. UA criterion 3.1 (≥3+ heme and ≤5 RBCs) met by 2.0% demonstrated a specificity of 96.7% and sensitivity of 16.7% included the highest proportion of patients with CK measurement (45.3%), and more than a quarter of those tested had levels consistent with RM.
conclusionsRM-suspected patients with greater heme/RBC discrepancy on UA were more likely to be tested for serum CK levels and diagnosed with RM. CK testing was uncommon under all definitions, suggesting missed RM cases. Automated electronic screening of UA parameters with clinical decision support to order CK may be a viable mechanism to increase the diagnosis of RM among AKI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.